Song Chunli, Jiao Zijun, Hou Zhanfeng, Xing Yun, Sha Xinrui, Wang Yuechen, Chen Jiaxin, Liu Susheng, Li Zigang, Yin Feng
State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen 518118, China.
JACS Au. 2024 Jul 11;4(8):2915-2924. doi: 10.1021/jacsau.4c00278. eCollection 2024 Aug 26.
PROTAC (Proteolysis TArgeting Chimeras) is a promising therapeutic approach for targeted protein degradation that recruits an E3 ubiquitin ligase to a specific protein of interest (POI), leading to its degradation by the proteasome. Recently, we developed a novel split-and-mix PROTAC system based on liposome self-assembly (LipoSM-PROTAC) which could achieve target protein degradation at comparable concentrations comparable to small molecules. In this study, we expanded protein targets based on the LipoSM-PROTAC platform and further examined its therapeutic effects . Notably, this platform could efficiently degrade the protein level of MEK1/2 in A375 cells or Alk in NCI-H2228 cells and display obvious tumor inhibition (60-70% inhibition rate) with negligible toxicity. This study further proved the LipoSM-PROTAC's application potentials.
蛋白酶靶向嵌合体(PROTAC)是一种很有前景的靶向蛋白质降解治疗方法,它将E3泛素连接酶招募到特定的目标蛋白(POI)上,导致其被蛋白酶体降解。最近,我们基于脂质体自组装开发了一种新型的拆分混合PROTAC系统(LipoSM-PROTAC),该系统在与小分子相当的浓度下就能实现目标蛋白的降解。在本研究中,我们基于LipoSM-PROTAC平台扩展了蛋白质靶点,并进一步研究了其治疗效果。值得注意的是,该平台能够有效降低A375细胞中MEK1/2的蛋白水平或NCI-H2228细胞中Alk的蛋白水平,并显示出明显的肿瘤抑制作用(抑制率为60-70%),且毒性可忽略不计。本研究进一步证明了LipoSM-PROTAC的应用潜力。